Ben Naccarato
Analyst · Bill Nasgovitz with Heartland Advisors. Please proceed with your question
Thank you, Mark. Beginning with revenue, our total revenue from continuing operations for the fourth quarter was $11.7 million compared to last year's fourth quarter of $12.6 million, a decrease of $851,000 or 6.8%. Our Treatment Segment revenue increased by $333,000 in the quarter compared to prior year due to increases in both receipt and production volume at our plants. The Service Segment was lower than prior year by $1.2 million due to lower project revenue, which is timing related and was impacted by the completion of certain phases of one of our ongoing contracts. For the year ended 2018, revenue was $49.5 million compared to $49.8 million in 2017. Our Services Segment increased -- revenue increased by $1.2 million as we performed more scope with one of our ongoing customers compared to prior year. Our Treatment Segment revenue was lower by $1.5 million due to lower processing and disposal revenue compared to prior year. The offset of this drop in revenue, though, at the Treatment Segment was a sharp increase in our opening waste backlog to $11.1 million compared to $7.7 million at the end of '17. Turning to our cost of sales. Our total cost of sales was $10.5 million in the fourth quarter compared to $10.8 million in the prior year, a decrease of $322,000 or 3%. Our Treatment Segment costs increased by $443,000 compared to prior year. Included in this increase was cost of sales of $1 million closure reserve booked at the M&EC facility compared to a smaller increase of $850,000 in Q4. Cost of sales from our Services Segment were down $765,000, consistent with the drop in project revenue. Gross profit for the quarter was $1.3 million compared to $1.8 million in 2017. Lower revenue at our Services Segment and the additional costs related to M&EC in the Treatment Segment were the main reasons for this drop. For the year ended '18, gross profit was $8.5 million compared to $8.6 million in '17. We had a modest improvement in our margin from revenue mix, but that was offset by the impact of the lower volume, and lower fixed costs were offset by the higher M&EC costs. Our G&A costs for the quarter were $2.7 million compared to $2.8 million last year, a decrease of about $84,000, and lower bad debt was offset by higher marketing and payroll costs. For the year-end 2018, our G&A costs were $10.7 million compared to $11.1 million in the prior year. And as with the quarter, lower bad debt was offset by higher marketing and payroll costs. Our research and development expenses were higher than prior year by $396,000, reflecting the write-down of certain assets in our Medical Segment. Our loss from continuing operations, net of taxes, for the quarter was $2.4 million compared to $340,000 last year. Included in this loss was a $1 million of additional closure reserves booked at M&EC, the continuing operating expenses at M&EC of $308,000 and the write-off of certain assets at our Medical Segment of $455,000. The net loss from continuing operations for the year ended December 31 was $1.1 million compared to net loss of $3.5 million in the prior year. Excluding all the income and expenses related to M&EC and the write-down of the Medical Segment, net income would have improved by $2.6 million. Net loss attributable to common shareholders for the quarter was $2.4 million compared to last year's net income of $2.6 million. For the year ended December 31, net loss attributable to common shareholders was $1.4 million compared to $3.7 million in the prior year. Our total loss per share for the quarter was $0.20 compared to income per share of $0.02 in the prior year. And our loss per share for the year ended 12/31/18 was $0.12 compared to $0.31 in the prior year. Our adjusted EBITDA from continuing operations for the quarter, as defined in this morning's press release, was a negative $167,000 compared to $329,000 last year. For the year ended August '18, adjusted EBITDA was $2 million compared to $2.4 million in 2017. Turning to the balance sheet. In comparison to our year-end of '17, our cash balance dropped by $253,000. Our current unbilled receivables were down by $1.4 million, reflecting improved billing and the completion of most of the outstanding M&EC invoicing. Other current assets were down $673,000 due to the reduction of prepaid at M&EC and the write-down of an asset at -- in the Medical Segment. Intangibles and other assets were down $333,000 due to the elimination of M&EC's long-term unbilled receivables and the write-down of a prepaid asset in our Medical Segment. Our current liabilities were up $1.9 million primarily due to increased accounts payable related to the M&EC closure. Our waste backlog sits at $11.1 million compared to $7.7 million at year-end '17. Our long-term liabilities were down $1.7 million as a result of the elimination of our preferred share dividends payable at M&EC in the second quarter and a decrease in our deferred tax liability, which netted down against our indefinite lived deferred tax assets or tax net operating loss carry forwards generated in 2017. Our current debt, including capital leases and excluding debt issuance costs, was $1.4 million, with $1.2 million due to our primary lender, PNC Bank. Total debt at year-end was $3.8 million, including capital leases and excluding debt issuance costs, was $3.4 million due to our primary lender, PNC Bank. Our current working capital was a negative $6.7 million compared to a negative $2.3 million in '17. A couple things should be noted, however. $5 million of cash collateral which we expect to receive upon closure of the M&EC facility is still listed as long-term asset. And when received, we will use this to reduce the working capital debts. In addition, we've just closed on $2.5 million of sub-debts with favorable terms that will further improve our liquidity position. Next, I'll summarize our cash flow for 2018. Cash provided by continuing operations at -- continuing operating activities was $2.6 million. Our cash used by discontinued ops was $618,000. Our cash used by investing activities was $1.4 million primarily on cash spending. Proceeds for the sale of discontinued ops property was $67,000. Cash used for financing was $580,000 consisting of $1.2 million payment on our term loan and $639,000 received from the revolver. With that, I'll now turn over the call to questions.